This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genocea Biosciences Valuation

Is 0A51 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A51 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0A51's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0A51's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A51?

Key metric: As 0A51 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0A51. This is calculated by dividing 0A51's market cap by their current revenue.
What is 0A51's PS Ratio?
PS Ratio	0.003x
Sales	US$1.91m
Market Cap	US$5.88k

0A51 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 0A51's PS Ratio compare to its peers?

The above table shows the PS ratio for 0A51 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.3x
RENE ReNeuron Group	7.7x	n/a	UK£1.9m
APTA Aptamer Group	7.6x	n/a	UK£6.5m
TCF Theracryf	5.8x	-150.1%	UK£2.3m
HGEN.Q Humanigen	0.00007x	n/a	US$119.0
0A51 Genocea Biosciences	0.003x	n/a	US$5.9k

Price-To-Sales vs Peers: 0A51 is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (3.6x).

Price to Sales Ratio vs Industry

How does 0A51's PS Ratio compare vs other companies in the GB Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	7.9x	19.4%
0A51 Genocea Biosciences	0.003x	n/a	US$5.88k
GNS Genus	1.7x	3.5%	US$1.41b
OXB Oxford Biomedica	4.5x	21.0%	US$554.49m

7 Companies		Estimated Growth	Market Cap
Industry Avg.	7.9x	37.0%
0A51 Genocea Biosciences	0.003x	n/a	US$5.88k

No more companies

Price-To-Sales vs Industry: 0A51 is good value based on its Price-To-Sales Ratio (0x) compared to the UK Biotechs industry average (19.6x)

Price to Sales Ratio vs Fair Ratio

What is 0A51's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A51 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.003x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0A51's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

1.5%

14.6%

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

-16.2%

22.2%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

-1.7%

-6.3%